TICKERNERD
Menu
PRGOPRGOHealthcare · Drug Manufacturers - Specialty & Generic

PRGO Stock Forecast: Perrigo Co. Plc Price Predictions for 2026-2027

Last close, 21 Aug 2026
$14
+4.01% on the day

The 5 Wall Street analysts covering Perrigo Co. Plc hold a median 12-month price target of $16 — +12.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 69 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$2.0B
Ticker Nerd rank
69 / 100
Median analyst target
$16
Analysts covering
5
Total return, dividends reinvested
1W
+9.3%
1M
+36.1%
YTD
+7.3%
1Y
−35.5%
From 52W high
−38.3%
From 52W low
+58.0%
$9
$23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PRGO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Perrigo Co. Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
69 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
98
Value
98
Issuance
85
Quality
64
Volatility
60
Revisions
55
Size
37
Growth
24
Momentum
11

Accruals (98): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (11): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PRGO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PRGO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20Oct 25Jan 26Apr 26Jul 26PRGOHigh $20Median $16Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
2 Buy3 Hold0 Sell
Low $14Median $16High $20

The green dot is the last close — the median target sits +12.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 Feb 2026Canaccord GenuityMaintainsBuy$20 → $17
15 Dec 2025JP MorganMaintainsNeutral—
6 Nov 2025Canaccord GenuityMaintainsBuy—
6 Nov 2025JP MorganDowngradeNeutral—
27 Oct 2025JefferiesMaintainsHold—
7 Aug 2025Canaccord GenuityMaintainsBuy—
7 Aug 2025JP MorganMaintainsOverweight—
6 Jan 2025Piper SandlerDowngradeNeutral—
30 Sept 2024Canaccord GenuityMaintainsBuy—
23 Sept 2024JefferiesDowngradeHold—
11 July 2024Piper SandlerMaintainsOverweight—
13 June 2024Piper SandlerMaintainsOverweight—
12 Apr 2024Canaccord GenuityMaintainsBuy—
8 Apr 2024Piper SandlerMaintainsOverweight—
28 Feb 2024JP MorganMaintainsOverweight—
17 Nov 2023Piper SandlerInitiatesOverweight—
9 Aug 2023JP MorganMaintainsOverweight—
7 Mar 2023Canaccord GenuityInitiatesBuy—
6 Mar 2023Raymond JamesMaintainsOutperform—
9 Nov 2022Raymond JamesMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PRGO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PRGO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+3.8%
Analysts raising
4
Analysts cutting
0
Fundamentals

Perrigo Co. Plc (PRGO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2818.0×

Cheaper than 1% of US stocks

Price / sales
0.5×

Cheaper than 84% of US stocks

Price / book
0.8×

Cheaper than 80% of US stocks

EV / EBITDA
8.1×

Cheaper than 45% of US stocks

Growth & margins
Revenue growth (YoY)
−3.2%

Higher than 22% of US stocks

Earnings growth (YoY)
−3.2%

Higher than 32% of US stocks

Gross margin
30.7%

Higher than 36% of US stocks

Operating margin
3.8%

Higher than 52% of US stocks

Net margin
−41.9%

Higher than 11% of US stocks

Returns & dividend
Return on equity
−48.7%

Higher than 21% of US stocks

Return on assets
2.0%

Higher than 58% of US stocks

Dividend yield
8.1%

Higher than 89% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PRGO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
PRGOPerrigo Co. Plc$2.0B
69
ETONEton Pharmaceuticals, Inc.$1.8B
99
TRLVTrulieve Cannabis Corp.$2.1B
88
ALVOAlvotech$1.7B
26
ANIPANI Pharmaceuticals, Inc.$1.7B
95
BHCBausch Health Cos., Inc.$2.4B
96
BCRXBioCryst Pharmaceuticals, Inc.$2.4B
86

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Perrigo Co. Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PRGO news & analysis

Perrigo: The Rebound Is Just Getting Started

Seeking Alpha · 13 Aug 2026positive

A Seeking Alpha analyst piece on Perrigo describes the company as substantially undervalued, citing recent quarterly earnings per share and revenue beats, market share gains, and improving fundamentals despite a soft over-the-counter market. It also highlights management's focus on cost control, debt reduction, and dividend growth.

Why it matters — PRGO watchers would care because the article points to strengthening operational results and financial discipline that could support Perrigo longer-term.

PRGO vs. NEOG: Which Stock Is the Better Value Option?

Zacks Investment Research · 10 Aug 2026neutral

Zacks Investment Research published an article comparing Perrigo (PRGO) and Neogen (NEOG), both in the Medical - Products sector, to determine which may offer better value to investors seeking undervalued stocks.

Why it matters — This piece positions Perrigo against a comparable peer, offering PRGO watchers an assessment of its relative value within the medical products sector.

Are Investors Undervaluing Perrigo (PRGO) Right Now?

Zacks Investment Research · 10 Aug 2026neutral

Zacks Investment Research shares commentary on Perrigo, applying its valuation framework that weighs earnings-estimate revisions alongside value, growth, and momentum trends to question whether the stock is currently undervalued. The piece is a general analytical discussion rather than a report of a specific corporate event.

Why it matters — PRGO watchers would care because it highlights how analytical attention is being focused on the stock's valuation and earnings-estimate trends amid its broader business performance.

Perrigo Q2 Earnings Call Highlights

MarketBeat · 9 Aug 2026neutral

Perrigo reported second-quarter 2026 results that exceeded its internal earnings expectations, though sales declined amid soft consumer self-care categories, retailer inventory reductions and a slower start to seasonal demand. The company maintained its full-year outlook, citing improving category trends, market-share gains and expected second-half contributions from innovation, distribution and demand-generation efforts.

Why it matters — Perrigo watchers would note that the company beat internal earnings expectations and reaffirmed its full-year outlook despite current sales softness, signalling confidence in its second-half plans.

Perrigo Stock Rises 23% as Q2 Earnings & Sales Beat Estimates

Zacks Investment Research · 6 Aug 2026positive

Perrigo reported Q2 earnings and sales that beat estimates, with Infant Formula sales rising and helping offset softer demand and divestiture impacts. The company reaffirmed its 2026 guidance, and the stock rose 23% following the results.

Why it matters — The results and reaffirmed guidance provide an updated picture of Perrigo's performance for PRGO watchers after a period of demand softness and divestiture-related changes.

FAQ

Frequently asked questions about PRGO stock

What is the PRGO stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Perrigo Co. Plc have a median 12-month price target of $16, with estimates ranging from $14 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PRGO stock a buy right now?

Of the 5 analysts covering Perrigo Co. Plc, 2 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Perrigo Co. Plc 69 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PRGO?

As at 22 Aug 2026, Perrigo Co. Plc ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (98 of 100).

Will PRGO stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +12.3% from the last close, and Ticker Nerd's factor model ranks Perrigo Co. Plc 69 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PRGO stock forecast for 2030?

No analyst covering Perrigo Co. Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRGO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $20 over the next 12 months.

How has PRGO stock performed over the past year?

Perrigo Co. Plc returned -35.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Perrigo Co. Plc do?

Perrigo Company plc is a consumer self-care and healthcare products company headquartered in Dublin, Ireland, with operational leadership in Grand Rapids, Michigan. It focuses on providing over-the-counter health and wellness solutions and infant formula that consumers can use to manage common conditions without a prescription.

What is the latest news on PRGO?

The most recent item we track (Seeking Alpha, 13 Aug 2026): "Perrigo: The Rebound Is Just Getting Started". A Seeking Alpha analyst piece on Perrigo describes the company as substantially undervalued, citing recent quarterly earnings per share and revenue beats, market share gains, and improving fundamentals despite a soft over-the-counter market. It also highlights management's focus on cost control, debt reduction, and dividend growth.

Company

About Perrigo Co. Plc.

Perrigo Company plc is a consumer self-care and healthcare products company headquartered in Dublin, Ireland, with operational leadership in Grand Rapids, Michigan. It focuses on providing over-the-counter health and wellness solutions and infant formula that consumers can use to manage common conditions without a prescription. Perrigo’s portfolio spans categories such as upper respiratory, digestive health, pain and sleep aids, healthy lifestyle, women’s health, skin health, infant formula, and oral care. The company operates through two primary business segments: Consumer Self-Care Americas, covering the United States and Canada, and Consumer Self-Care International, which serves Europe, Australia, and other markets. Perrigo is a major provider of store-brand private label self-care products for retailers, complemented by a range of branded products including well-known names such as Opill, Mederma, Compeed, and EllaOne. Its products are distributed through retailers, pharmacies, and e-commerce channels, making Perrigo a significant player in accessible, high-quality self-care solutions across North America and Europe.

CEO Mr. Patrick Lockwood-Taylor · 8,100 employees · Ireland · https://www.perrigo.com